Clinical trials
Patients With Advanced Solid Tumors clinical trials
Below are recruiting patients with advanced solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,036 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06783569RecruitingPhase 1
First-in-human study for advanced solid tumors
This trial tests a new experimental drug for people with advanced solid tumors that have not responded to standard treatments. It aims to find a safe dose and see if the drug can shrink tumors.
Harbin, Heiljiang ProvinceAges 18 years+ - NCT03772561RecruitingPhase 1
Testing AZD5363, olaparib, and durvalumab for advanced solid cancers
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
Singapore, SingaporeAges 21–99 - NCT05701709RecruitingPhase 1
First-in-human test for a new drug in advanced solid cancers
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05978102RecruitingPhase 1/Phase 2
Study of STI-7349 for advanced solid cancers
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
Yiwu, ZhejiangAges 18–80 - NCT05217693RecruitingPhase 1
First study drug BB-1705 for advanced solid tumors
This Phase 1 trial tests BB-1705 in people with advanced or metastatic (spread) solid tumors that cannot be removed with surgery. It mainly focuses on safety and how the drug behaves in the body, and may offer an option for patients when standard treatments have not worked.
BeijingAges 18–78 - NCT06773091RecruitingPhase 1
NK cell therapy for advanced solid tumors
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
BeijingAges 18–70 - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05035745RecruitingPhase 1/Phase 2
Selinexor plus talazoparib for advanced triple-negative breast cancer
This trial tests selinexor plus talazoparib in people with advanced, treatment-resistant solid tumors and, separately, advanced triple-negative breast cancer. It aims to see whether this combination can shrink tumors or slow their growth when standard options have not worked.
SingaporeAges 18–99 - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99 - NCT06208410RecruitingPhase 1/Phase 2
JS105 plus other treatments for advanced solid tumors
This trial tests a new drug called JS105 combined with other anti-cancer therapies for people with certain advanced breast, ovarian, endometrial, or cervical cancers. It aims to find out if these combinations are safe and effective.
Zhengzhou, HenanAges 18–75 - NCT06770569RecruitingPhase 1
Study of HRS-3802 for advanced solid tumors
This trial tests an experimental drug called HRS-3802 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how the body processes it.
Saint Leonards, New South WalesAges 18 years+ - NCT06760819RecruitingPhase 2
Sevacertinib for solid tumors with HER2 mutations
This study tests an oral tablet called sevacertinib in people with solid tumors (not lung cancer) that have a HER2 mutation. It aims to see how well the drug works and how safe it is for people who have tried other treatments or have no good options left.
Birmingham, AlabamaAges 18 years+ - NCT06220838RecruitingPhase 1
Study of SC-101 for advanced solid tumors
This trial tests a new drug called SC-101 in people with advanced solid tumors that have not responded to other treatments. It may be an option if your tumor shows a specific protein called Nectin-4, which the drug targets.
Beijing, Beijing MunicipalityAges 18–80 - NCT06710158RecruitingPhase 1
SC-102 for advanced solid tumors
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06752681RecruitingPhase 1
Testing day301 for advanced solid tumors
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT06739291RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new oral drug called SIGX1094R for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how well it works, and it requires a tumor tissue sample to look for a specific marker.
BeijingAges 18 years+ - NCT06736275RecruitingEarly Phase 1
Testing a new gene therapy for advanced solid tumors
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
BeijingAges 18–75 - NCT06727812RecruitingPhase 1
Testing a new targeted therapy for advanced solid tumors
This trial tests a new drug called HRS-6208 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the cancer.
Nanjing, JiangsuAges 18–75 - NCT06737731RecruitingPhase 1/Phase 2
SHR-1681 for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called SHR-1681 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06726148RecruitingPhase 1/Phase 2
Study of ECI830 for advanced breast cancer and solid tumors
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
Los Angeles, CaliforniaAges 18–100 - NCT06717750RecruitingPhase 1
Experimental oral drug for advanced solid tumors
This study tests an experimental oral drug (CSCJC3456) that may target certain genetic changes (FGFR) in advanced cancers. It might be an option if your cancer has not improved with standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06724016RecruitingPhase 1
Study of HM16390 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug, HM16390, either by itself or combined with pembrolizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT06718621RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an experimental drug called BL-M08D1 for people with solid tumors that have spread or cannot be removed by surgery and have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Patients With Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patients with advanced solid tumors?
- Yes. Clin2 currently lists 1,036 recruiting patients with advanced solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patients with advanced solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patients with advanced solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Advanced Solid Tumor
- Advanced Malignant Solid Neoplasm
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.